title: [Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
abstract: Modern methods for the evaluation of drug interaction at the level of biotransformation system are discussed with special reference to the lidocaine test (MEGX) and measurement of cytochrome P-450 activity in patients with drug-induced oxidative processes in the liver. Interaction of atorvastatin with clopidogrel are shown to slightly reduce the desaggregative effect of the latter. It is concluded that MEGX test widens opportunities for personalization and safe pharmacotherapy.
authors.forename: A S
authors.initials: AS
authors.lastname: Sivkov
authors.forename: S V
authors.initials: SV
authors.lastname: Paukov
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Ruvinov
authors.forename: I V
authors.initials: IV
authors.lastname: Kukes
mesh_terms: D000069059:Atorvastatin; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D004790:Enzyme Induction; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000201:enzymology; D010599:Pharmacokinetics; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D057285:Precision Medicine; D011758:Pyrroles / Q000009:adverse effects; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D000077144:Clopidogrel; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D013988:Ticlopidine